Chimerix said today it will develop Cantex Pharmaceuticals’ Phase III-bound CX-01 as a first-line treatment for Acute Myeloid Leukemia (AML) and possibly other blood cancers, through an exclusive ...
BELTSVILLE, Md., Nov. 15, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (NXTC) (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class ...
Examining protein changes in peripheral blood cells just 24 hours after initiating chemotherapy for acute myeloid leukemia (AML) could predict 5-year overall survival, potentially allowing treatment ...
•Genomic characterization determines diagnosis, classification, and prognostication of the myeloid malignancies myelodysplastic syndrome (MDS) and AML. •Recognizing genetic lesions as invariable ...
SEATTLE, WA / ACCESSWIRE / November 20, 2024 / Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on ...
A series of blood tests, procedures, and imaging tests can help diagnose acute myeloid leukemia (AML). Additionally, these tests can also determine its subtype and help identify the best treatment ...
Hosted on MSN
Failure in a CAR T cell trial could unlock multiple treatments for acute myeloid leukemia
In the clinical battle against leukemia, recent breakthroughs in chimeric antigen receptor T cells (CAR T) have given patients and doctors an unprecedented weapon. CAR T cell therapy has demonstrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results